![Julie Hambleton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Julie Hambleton
Directeur/Membre du Conseil chez
ERASCA, INC.
Fortune : 77 040 $ au 31/05/2026
Profil
Julie Hambleton currently works at Erasca, Inc., as Independent Director from 2021, Onc.ai, Inc., as Independent Director, and Gennao Bio, Inc., as Independent Director from 2021.
Dr. Hambleton also formerly worked at Arch Oncology, Inc., as President, Chief Executive Officer & Director from 2020 to 2021, Genentech, Inc., as Medical Director-Global Clinical Development from 2003 to 2010, Accent Therapeutics, Inc., as Director from 2020 to 2021, IGM Biosciences, Inc., as Independent Director from 2018 to 2025, Springworks Therapeutics, Inc., as Independent Director from 2020 to 2025, Bristol Myers Squibb Co., as Vice President & Head-US Medical from 2016 to 2017, Five Prime Therapeutics, Inc., as Chief Medical Officer & Executive Vice President from 2015 to 2016, The University of California, San Francisco, as Associate Professor from 1993 to 2003, Clovis Oncology, Inc., as Vice President-Clinical Development from 2010 to 2012, and IDEAYA Biosciences, Inc., as Chief Medical Officer, SVP & Head-Development from 2018 to 2020.
Dr. Hambleton received her undergraduate degree from Duke University and doctorate degree from Case Western Reserve University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ERASCA, INC. 0 % | 15/04/2026 | 6 000 ( 0 % ) | 77 040 $ | 31/05/2026 |
Postes actifs de Julie Hambleton
| Sociétés | Poste | Début |
|---|---|---|
| ERASCA, INC. | Directeur/Membre du Conseil | 29/03/2021 |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted nucleic acid therapeutics to cure muscle diseases | Directeur/Membre du Conseil | 13/07/2021 |
Onc.ai, Inc.
 Onc.ai, Inc. Packaged SoftwareTechnology Services Develops precision oncology care management platform that aims to transform clinical decision making | Directeur/Membre du Conseil | - |
Anciens postes connus de Julie Hambleton
| Sociétés | Poste | Fin |
|---|---|---|
| IGM BIOSCIENCES, INC. | Directeur/Membre du Conseil | 14/08/2025 |
| SPRINGWORKS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/07/2025 |
Arch Oncology, Inc.
 Arch Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company that develops biologic therapies for treatment of patients with tumors and hematologic malignancies | Directeur Général | 01/04/2021 |
Accent Therapeutics, Inc.
 Accent Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops treatments for cancer patients | Directeur/Membre du Conseil | 01/03/2021 |
| IDEAYA BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 30/04/2020 |
Formation de Julie Hambleton
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
89
Relations au 1er degré
15
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 15 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops protein therapeutics for cancer and inflammatory diseases | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as an biopharmaceutical company that acquires, develops and commercializes innovative anti cancer agents | Health Technology |
Arch Oncology, Inc.
Arch Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company that develops biologic therapies for treatment of patients with tumors and hematologic malignancies | Health Technology |
Case Western Reserve University School of Medicine
 Case Western Reserve University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IDEAYA Biosciences, Inc.
 IDEAYA Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as oncology-focused precision medicine company which develops and sells cancer therapeutics | Health Technology |
IGM Biosciences, Inc.
 IGM Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops engineered IgM antibodies for the treatment of cancer patients | Health Technology |
Accent Therapeutics, Inc.
Accent Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops treatments for cancer patients | Health Technology |
Erasca, Inc.
 Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Springworks Therapeutics, Inc.
 Springworks Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes medicines for nervous system disorders | Health Technology |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Develops precision oncology care management platform that aims to transform clinical decision making | Technology Services |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted nucleic acid therapeutics to cure muscle diseases | Health Technology |
